热疗联合肝动脉化疗栓塞治疗原发性肝癌的临床疗效观察  

The efficacy of hyperthemia integrated with transcatheter hepatic artery chemoembolization in treatment of primary liver cancer

作　　者：马兆明[1] 李德凡[1] 张胜[1] 杨帆[1] 蒋淑年[1] 

机构地区：[1]江苏省连云港市第二人民医院放疗科,222023

出　　处：《中国厂矿医学》2009年第6期655-656,共2页Chinese Medicine of Factory and Mine

摘　　要：目的探讨热疗联合肝动脉化疗栓塞治疗原发性肝癌的临床疗效。方法55例原发性肝癌随机分为2组,治疗组24例采用热疗联合肝动脉化疗栓塞;对照组31例单纯肝动脉化疗栓塞。比较2组的临床疗效及1、2年的生存率,并观察毒副反应。结果治疗组CR+PR20例,有效率83.3%,SD+PD4例;对照组CR+PR18例,有效率58.1%,SD+PD13例。治疗组有效率高于对照组,2组间差异有统计学意义(P<0.05)。治疗组与对照组1年生存均为19例,2年生存分别12例和5例,2组1年生存率无差异(79.2%vs61.3%,P>0.05),2年生存率治疗组高于对照组(50.0%vs16.1%,P<0.05)。治疗组未见毒副反应增加。结论热疗联合肝动脉化疗栓塞治疗原发性肝癌的效果优于单纯肝动脉化疗栓塞。Objective To observe the efficacy of hyperthermia integrated with transcatheter hepatic artery chemoembolization in the treatment of primary liver cancer. Methods Fifty-five cases of primary liver cancer were randomized into two groups ： group A （ n = 24） with treatment of hyperthermia combined with transcatheter hepatic artery ehemoembolization and group B （ n = 31 ） with treatment of transcatheter hepatic artery ehemoembolization alone. The effects and survival rates of 1,2 years were compared in two groups. Results The effect rate in group A was higher than that in group B （83. 3% vs 58. 1% ,P 〈 0. 05 ）. In group A,The survival rates of 1,2years were 79. 2% （19/24） and 50. 0% （12/24） respectively ; in group B, the survival rates of 1,2 years were 61.3 % （ 19/31 ） and 16. 1% （ 5/31 ） respectively. Survival rates of 1 -year had no difference in two groups （ P 〉 0. 05 ）, but survival rate of 2-year in group A was higher than that in group B （ P 〈 0. 05 ）. Compared with group B,there was no increasing of adverse effects in group A. Conclusions Hyperthermia combined with transeatheter hepatic artery chemoembolization for primary liver cancer is a safe and effective regimen ,and is worthy of promotion and further study.

关 键 词：肝肿瘤 热疗 肝动脉化疗栓塞 

分 类 号：R735.7[医药卫生—肿瘤]